LinkedInXFacebook
Subscribe
Orthopedics This Week
  • Opinions
  • |My Feed
  • |Events
  • |Company Directory
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Licensing Deal Signals Progress for Novel RA Treatment
Company News Premium

Licensing Deal Signals Progress for Novel RA Treatment

November 6, 2025 1 min read Premium comments

Advertisement

Licensing Deal Signals Progress for Novel RA Treatment
Source: Teijin Pharma Limited and Elevara Medicines Limited
PremiumElevara MedicinesTCK-276Teijin GroupTeijin Pharma

Rheumatoid arthritis (RA) may be an autoimmune disease, but its collateral damage — erosion of cartilage, joint deformity, and synovial hypertrophy — lands squarely in orthopedic territory.

Most Popular

Join 13,000+ Subscribers

Get unlimited access to OTW reporting, member discussions, and the weekly newsletter.

13,000+ subscribers
  • Every OTW article, fully unlocked
  • Member comments and discussion
  • The weekly orthopedic business briefing

Author

KD
Kim DelMonico
React:

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

Orthopedics This Week’s mission is to connect the orthopedic community with the people, ideas, and innovations shaping the future of musculoskeletal care.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Opinions
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, opinions, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy